- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05425966
Adapting a Web-Based Professional Development for Mexican School Mental Health Providers Delivering Evidence-Based Intervention for ADHD and ODD
March 15, 2024 updated by: University of California, San Francisco
Adapting a Remote Training for Mexican School Clinicians Delivering Evidence-Based Intervention for ADHD and ODD
Neurodevelopmental disorders of inattention and disruptive behavior, such as Attention-Deficit/ Hyperactivity Disorder (ADHD) and Oppositional Defiant Disorder (ODD), are among the most common youth mental health conditions across cultures.
An efficacious and feasible solution to improving affected youth's ADHD/ODD is training existing school clinicians to deliver evidence-based intervention with fidelity.
Despite initial promising results of training school clinicians to treat ADHD/ODD in settings suffering from high unmet need, such as Mexico, scalability is limited by a lack of researchers with capacity to train, monitor, and evaluate school clinicians in such efforts on a large scale.
Thus, there is a need to develop more feasible interventions and training programs for school clinicians, as well as create a system with capacity for scalable training and evaluation, to combat the widespread impact ofADHD/ODD worldwide.
Converting interventions and school clinician professional development programs for fully-remote delivery allows for more flexibility, accessibility, affordability, scalability, and promise for ongoing consultation than in-person options.
Supporting scalable training for school clinicians could address a significant public health concern in Mexico, as only 14% of Mexican youth with mental health disorders receive treatment and less than half of those treated receive more than minimally adequate care.
The study team is uniquely suited for this effort, given that they developed the only known school-homeADHD/ODD evidence-based intervention in Latin America-and-have developed a web-based training for U.S. school clinicians with promising preliminary results.
The study team's prior studies and high levels of unmet need make Mexico an ideal location for this proposal; however, lessons learned could be used to expand scalable school clinician training for evidence-based intervention in other settings and/or for other disorders.
Thus, this study focuses on conducting an open-trial of the fully-remote program and make iterative changes.
It is predicted that: H1) school clinicians trained remotely will be satisfied and show improved evidence-based practice skills; H2)families and teachers participating remotely will be satisfied and youth will show improved ADHD/ODD; H3) observation/feedback from a 3-school open-trial will guide iterative changes to the remote program.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
67
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94104
- UCSF
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Students meeting the following criteria are eligible:
- at least six inattention symptoms and/or six hyperactive/impulsive symptoms endorsed by parent or teacher as occurring often or very often,
- at least one area of impairment rated as concerning by both parent and teacher, and
- a parent and teacher agreeing to participate.
- Students taking medication are eligible as long as regimens were stable.
- Parents and teachers and school clinicians of participating are eligible to participate.
Exclusion Criteria:
All Participants: Anyone who does not speak and read Spanish will be excluded, given that all informed consent, measurement, and activity procedures will be conducted in Spanish.
Child Participants
- Children taking medication will be eligible for screening after the child has been on a stable medication regimen for at least one month (to minimize chance that treatment effects are due to medication and not the proposed program).
- Presence of conditions that are incompatible with this study's treatment.
- severe visual or hearing impairment,
- severe language delay,
- psychosis,
- Child does not read or speak Spanish (inability to complete assessment measures or participate in group treatments).
- Child is in an all-day special education classroom. Children in these classrooms are frequently receiving intensive behavior modification programs and assistance such that the teacher consultation component would be expected to require modification for use in these settings.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: CLS-R-FUERTE
Active program participation in: a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5).
via school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
|
The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5).
It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Child Symptom Inventory-4 (CSI-4) Parent Checklist (Oppositional Defiant Disorder) ODD Symptom Severity Score
Time Frame: Baseline and post treatment (8 weeks)
|
Parents will assess ODD symptoms using the CSI-4.
The CSI-4: Parent Checklist contains 9 symptoms of ODD.
Each symptom is rated on a 4-point scale (0= never to 3= very often).
The average ODD scores range from zero to four, with higher scores indicating more severe symptoms.
|
Baseline and post treatment (8 weeks)
|
|
Change in Child Symptom Inventory-4 (CSI-4) Teacher Checklist (Oppositional Defiant Disorder) ODD Symptom Severity Score
Time Frame: Baseline and post treatment (8 weeks)
|
Teachers will assess ODD symptoms using the CSI-4.
The CSI-4: Teacher Checklist contains 9 symptoms of ODD.
Each symptom is rated on a 4-point scale (0= never to 3= very often).
The average ODD scores range from zero to four, with higher scores indicating more severe symptoms.
|
Baseline and post treatment (8 weeks)
|
|
Change Impairment Rating Scale (IRS) Teacher Questionnaire Overall Severity Score
Time Frame: Baseline and post treatment (8 weeks)
|
Teachers will assess impairment using the IRS.
The IRS Teacher Questionnaire contains 8 items of functional impairment (i.e., academic and peer relations).
Each item is rated on a 7-point scale (1= no problem; does not need treatment/services to 7= extreme impairment; definitely needs treatment/services).
The average of all IRS scores range from one to seven, with higher scores indicating more severe impairment.
|
Baseline and post treatment (8 weeks)
|
|
Change Impairment Rating Scale (IRS) Parent Questionnaire Overall Severity Score
Time Frame: Baseline and post treatment (8 weeks)
|
Parents will assess impairment using the IRS.
The IRS Teacher Questionnaire contains 8 items of functional impairment (i.e., academic and peer relations).
Each item is rated on a 7-point scale (1= no problem; does not need treatment/services to 7= extreme impairment; definitely needs treatment/services).
The average of all IRS scores range from one to seven, with higher scores indicating more severe impairment.
|
Baseline and post treatment (8 weeks)
|
|
Change in Child Symptom Inventory-4 (CSI-4) Parent Checklist ADHD Combined Type Symptom Severity Score
Time Frame: Baseline and post treatment (8 weeks)
|
Parents will assess ADHD symptoms using the CSI-4.
The CSI-4: Parent Checklist contains 18 symptoms for ADHD, Combined type (ADHD:C; 18 items).
Each symptom is rated on a 4-point scale (0= never to 3= very often).
The average of ADHD:C scores range from zero to four, with higher scores indicating more severe symptoms.
|
Baseline and post treatment (8 weeks)
|
|
Change in Child Symptom Inventory-4 (CSI-4) Teacher Checklist ADHD Combined Type Symptom Severity Score
Time Frame: Baseline and post treatment (8 weeks)
|
Teachers will assess ADHD symptoms using the CSI-4.
The CSI-4: Teacher Checklist contains 18 symptoms for ADHD, Combined type (ADHD:C; 18 items).
Each symptom is rated on a 4-point scale (0= never to 3= very often).
The average of ADHD:C scores range from zero to four, with higher scores indicating more severe symptoms.
|
Baseline and post treatment (8 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Lauren M Haack, PhD, University of California, San Francisco
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2021
Primary Completion (Actual)
June 30, 2022
Study Completion (Actual)
June 30, 2022
Study Registration Dates
First Submitted
June 15, 2022
First Submitted That Met QC Criteria
June 15, 2022
First Posted (Actual)
June 21, 2022
Study Record Updates
Last Update Posted (Actual)
March 18, 2024
Last Update Submitted That Met QC Criteria
March 15, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLSRFUERTE
- R21MH124066 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
St. Antonius HospitalNot yet recruitingADHD | Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD, Predominantly Hyperactive - Impulsive | Attention Deficit Disorder (ADD) | Hyperactivity | Inattention | ADHD Predominantly Hyperactivity Type | ADHD-not Other Specified | Hyperactivity... and other conditions
-
Wuhan Sports UniversityTerminatedADHD | ADHD - Combined Type | ADHD - Inattentive Type | ADHD - Attention Deficit Disorder With Hyperactivity | ADHD Specifically With Executive Function ImpairmentChina
-
Hartford HospitalRecruiting
-
Universidad de GranadaNot yet recruiting
-
Chen LiRecruiting
-
Region SyddanmarkRecruiting
-
Alexandria UniversityCompleted
-
King's College LondonSouth London and Maudsley NHS Foundation TrustEnrolling by invitation
-
University of Milano BicoccaIRCCS Eugenio MedeaCompleted
Clinical Trials on CLS-R-FUERTE
-
University of California, San FranciscoNational Institute of Mental Health (NIMH)CompletedADHD | Oppositional Defiant DisorderUnited States
-
University of California, San FranciscoCompleted
-
University of California, San FranciscoFogarty International Center of the National Institute of HealthEnrolling by invitation
-
University of California, San FranciscoInstitute of Education SciencesTerminated
-
Biotronik SE & Co. KGTerminatedSinus Node DiseaseSpain, Hungary, Taiwan, Korea, Republic of, India, Singapore, Italy, China, Malaysia
-
University of California, San FranciscoSan Francisco Department of Public HealthCompletedMental Disorder in Adolescence | Trauma, Psychological | Adolescent - Emotional ProblemUnited States
-
University of Wisconsin, MadisonUnited Community Center; Centro Hispano; North/Eastside Senior Coalition; Latino... and other collaboratorsCompletedFalls PreventionUnited States
-
Biotronik, Inc.Completed
-
Fondazione Don Carlo Gnocchi OnlusUniversité Catholique de Louvain; Vrije Universiteit Brussel; University of Ljubljana and other collaboratorsCompletedTransfemoral AmputationItaly
-
Merit E. Cudkowicz, MDCalico Life Sciences LLCCompleted